RESUMO

Thrombocytopenia with life-threatening hemorrhage in childhood immune thrombocytopenic purpura is rare, but effective therapeutic options are limited for the patient with bleeding. We report the efficacy of humanized anti-CD20 monoclonal antibody (rituximab, Rituxan) therapy for an infant with severe, refractory life-threatening immune thrombocytopenic purpura.

Assuntos

Anticorpos Monoclonais/farmacologia , Anticorpos Monoclonais/uso terapêutico , Antígenos CD20/metabolismo , Antineoplásicos/farmacologia , Antineoplásicos/uso terapêutico , Púrpura Trombocitopênica Idiopática/tratamento farmacológico , Anticorpos Monoclonais Murinos , Humanos , Lactente , Masculino , Rituximab , Resultado do Tratamento

RESUMO

Recombinant avipoxvirus vectors are attractive candidates for use in vaccination strategies for infections such as human immunodeficiency virus type 1 (HIV-1), where induction of a CD8+ T cell response is thought to be an important component of protective immunity. Here, we report the expression of a multiepitope polypeptide (TAB9) composed of the central 15 amino acids of the V3 loop from six different isolates of HIV-1 in a fowlpox virus (FWPV) vector, and the use of this vector (FPTAB9LZ) to induce strong HIV-specific CD8+ T cell responses in mice. In animals immunized twice intravenously with FPTAB9LZ, almost 2% of the CD8+ T cells in the spleen were shown to produce IFN-gamma in response to stimulation with HIV-1 peptides 1 week after the second immunization. The most dominant response was to the HIV-1 IIIB peptide. A strong HIV-specific response was also induced by intraperitoneal immunization of mice with FPTAB9LZ, whilst subcutaneous immunization elicited a weaker response. Intraperitoneal immunization with FPTAB9LZ was also shown to provide protection against challenge with a recombinant vaccinia virus expressing antigens, including those in TAB9. These results confirm the potential of FWPV vectors for use in HIV vaccination strategies.

Assuntos

Linfócitos T CD8-Positivos/imunologia , Epitopos de Linfócito T/imunologia , Epitopos/imunologia , Vírus da Varíola das Aves Domésticas/imunologia , Vetores Genéticos/imunologia , Antígenos HIV/imunologia , Proteína gp120 do Envelope de HIV/imunologia , HIV-1/imunologia , Fragmentos de Peptídeos/imunologia , Peptídeos/imunologia , Animais , Linhagem Celular , Vias de Administração de Medicamentos , Epitopos/genética , Epitopos de Linfócito T/genética , Vírus da Varíola das Aves Domésticas/genética , Expressão Gênica , Vetores Genéticos/genética , Antígenos HIV/genética , Proteína gp120 do Envelope de HIV/genética , HIV-1/genética , Humanos , Injeções Intravenosas , Camundongos , Fragmentos de Peptídeos/genética , Peptídeos/genética , Recombinação Genética , Baço/citologia , Linfócitos T Citotóxicos/imunologia , Vacinação , Vaccinia virus